SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to a mixed reaction to earnings, with initial positive revenue overshadowed by a one-time tax charge and concerns about increased spending on AI infrastructure. The community is debating whether the dip is a buying opportunity or a sign of deeper issues with the company's investment strategy. Some investors believe the market is overreacting, while others are wary of Meta's increasing capital expenditures.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI is trending as the community rallies around its potential, emphasizing a conviction-based approach over hype. Talk centers on the token's strong community and resilience within the $SOL ecosystem, with many expressing a shared belief that 'we're all gonna make it.'

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid anticipation for an upcoming meeting between President Trump and China's President Xi, with trade deal hopes influencing market sentiment. Community members are actively discussing potential impacts on major tech companies following mixed earnings reports from key players like Microsoft and Meta, while some express concern about an over-reliance on a few top stocks. Investors are weighing the potential for further market gains against concerns about stretched valuations and the broader economic outlook.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending due to a significant post-earnings drop, sparking discussions about reduced guidance and declining customer traffic amid macroeconomic pressures. Community members are debating the company's valuation, food quality, portion sizes, and pricing, with some suggesting it's oversold and ripe for institutional investment while others point to waning popularity. The impact of tariffs and competition from other fast-casual restaurants like CAVA are also being considered.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as it surpasses a $5 trillion market cap, fueled by exceptionally strong AI chip demand and CEO Jensen Huang's forecast of $500 billion in cumulative revenue through 2026; the community is closely watching Trump's upcoming meeting with President Xi for potential easing of China's Blackwell restrictions, while also weighing the potential impact of increased capex from major tech companies like Microsoft and Meta.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending due to a significant stock drop following disappointing earnings and a lowered outlook, prompting analysts to downgrade the stock. The community is discussing potential corporate fraud, a management shakeup, and whether this presents a buying opportunity or a value trap. Some are hopeful for a quick bounce, while others are wary of deeper declines and possible investigations.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending amid ongoing speculation about a potential merger with Warner Bros. Discovery ($WBD), with discussions focusing on offer prices and deal structures. Community chatter revolves around whether a deal will materialize and its potential impact, particularly as analysts debate the value and future of the combined entity, while others point to upcoming earnings and layoffs as key events to watch.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors analyze the implications of the company's recent earnings report, particularly regarding its AI spending and Azure cloud growth. Community discussions revolve around whether the earnings justify the current valuation and forward guidance. The broader context includes Microsoft's significant stake in OpenAI and its ongoing competition in the cloud computing arena against companies like Amazon and Google.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending as traders discuss a potential short squeeze and the stock's undervaluation following recent earnings and future growth prospects. Community members are focused on potential price targets and the possibility of a buyout, while also analyzing short interest and options activity. Speculation about analyst upgrades and the impact of potential government actions are contributing to the heightened interest.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet's stock is trending as traders discuss the company's recent earnings beat and growing excitement around its AI and cloud computing initiatives. Community members are highlighting Google's AI strategy and potential for further growth, particularly compared to other tech giants. Some are also discussing the impact of Google's capital expenditure plans and partnerships in the AI space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nasdaq-listed shares of Autolus Therapeutics PLC (AUTL) were in the spotlight on Friday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-positive-chmp-opinion">announced</a> that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve its Obe-cel therapy for the treatment of a particular type of blood cancer.Obe-cel is short for Obecabtagene Autoleucel. The CHMP has recommended that the European Commission approve it for the treatment of adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia, an aggressive type of blood cancer that can also involve the lymph nodes, spleen, liver, central nervous system, and other organs.According to Autolus, there are about 6,000 new cases of acute Lymphoblastic Leukemia diagnosed every year in Europe.The committee’s recommendation was based on the results of the company’s open-label, multiple-centre study and will serve as the basis for the commission’s final decision on Autolus’ marketing authorization application.The European Commission's decision will apply to all 27 European Union Member States, Iceland, Norway, and Liechtenstein.Obe-cel received approval from the U.S. Food and Drug Administration in November 2024 and conditional marketing authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency in April.On Stocktwits, retail sentiment around AUTL improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘neutral’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_12_01_00_PM_png_a607fcc3b0.webp" alt="AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the therapy receiving approval in the EU.<stembedurl>https://stocktwits.com/Mancunian/message/615691105</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by about 42% this year and 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-backed-anthropic-claude-blackmails-engineer/ch0QVgWRbqH">Amazon-Backed Anthropic's AI Model Reportedly Blackmails Engineer Having An Affair To Avoid Being Shut Down In Test Run</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens

CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 

Equity

CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 


Autolus Therapeutics (AUTL) Gets a Buy from Truist Financial

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Autolus Therapeutics (AUTL Research Report). The...

China Universal Asset Management Co. Ltd. Invests $105,000 in Autolus Therapeutics plc (NASDAQ:AUTL)

China Universal Asset Management Co. Ltd. bought a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to its most recent 13F filing with the...

Autolus Therapeutics (NASDAQ:AUTL)  Shares Down 7.5%

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) dropped 7.5% during trading on Monday . The stock traded as low as $5.90 and last traded at $5.90. Approximately 1,050,329 shares were traded...

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-AL

Submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in r/r B-ALLThe US marketing application is under review with a Prescription Drug User Fee Act (PDUFA) target action...

Autolus Therapeutics (AUTL, $5.68) price exceeded its 50-day Moving Average on April 01, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Autolus Therapeutics plc (AUTL, $5.68) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that AUTL's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Autolus Therapeutics Announces Board Leadership Changes

The latest announcement is out from Autolus Therapeutics Plc (AUTL). John Johnson has stepped down from his role as the chair of Autolus Therapeuti...

Autolus Therapeutics Announces Changes to its Board of Directors

LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today...

Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL  Free Report) by 22.7% in the 3rd quarter, according to the company in its most recent filing with...

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Current Price	$1.46
Prev Close	$1.54
Open	$1.54
Dividend Yield	0.00%
50-Day Moving Average	$1.54
Beta	1.18
Avg. Volume	5.52M
PE Ratio	-1.70

52-Week High	$4.12
52-Week Low	$1.11
Market Capitalization	$409.86M
EPS (Annual)	-$0.8652
Price to Book	1.50
Revenue Per Employee	$15,648.00
Enterprise Value/EBITDA	N/A

AUTL
Autolus Therapeutics Ltd - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AUTL News

AUTLAutolus Therapeutics Ltd - ADR